• 1
    IST-3 Collaborative Group, Sandercock P, Wardlaw JM, Lindley RI et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379 (9834): 23522363.
  • 2
    Lyden PD. In anticipation of International Stroke Trial-3 (IST-3). Stroke 2012; 43: 16911694.
  • 3
    The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 1995; 333: 15811587.
  • 4
    Hacke W, Kaste M, Bluhmki E et al.; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 2008; 359: 13171329.
  • 5
    Hoffman JR. Thrombolysis for stroke: policy should be based on science, and not on politics, money or fear of malpractice. Emerg. Med. Australas. 2006; 18: 215218.
  • 6
    Hoffman JR, Cooper RJ. Stroke thrombolysis: we need new data (not more reviews). Lancet Neurol. 2005; 4: 204205.
  • 7
    Newman DH. Thrombolytics for acute ischemic stroke. The NNT: The NNT Group, 2010. Available from URL: [Accessed July 2012].
  • 8
    Hacke W, Furlan AJ, Al-Rawi Y et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009; 8: 141150.
  • 9
    Multicentre Acute Stroke Trial – Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346: 15091514.
  • 10
    The Multicentre Acute Stroke Trial – Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N. Engl. J. Med. 1996; 335: 145150.
  • 11
    Donnan G, Davis SM, Chambers BR et al., for the Australian Streptokinase Trial Investigators. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996; 276: 961966.
  • 12
    Hacke W, Kaste M, Fieschi C et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 10171025.
  • 13
    Saver JL, Gornbein J, Starkman S. Response to: ‘A graphic reanalysis of the NINDS Trial’. Ann. Emerg. Med. 2010; 55: 226227; author reply 229.
  • 14
    Dewey HM, Churilov L, Blacker D et al. Response to ‘A graphic reanalysis of the NINDS Trial’. Ann. Emerg. Med. 2010; 55: 227229; author reply 229.
  • 15
    Hoffman JR, Schriger DL. A graphic reanalysis of the NINDS Trial. Ann. Emerg. Med. 2009; 54: 329336; 36 e1–35.
  • 16
    Kimura K, Iguchi Y, Shibazaki K et al. Early stroke treatment with IV t-PA associated with early recanalization. J. Neurol. Sci. 2010; 295: 5357.
  • 17
    Hacke W, Kaste M, Fieschi C et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352 (9136): 12451251.
  • 18
    Chen CI, Iguchi Y, Grotta JC et al. Intravenous TPA for very old stroke patients. Eur. Neurol. 2005; 54: 140144.
  • 19
    Hadler NM. Rethinking Aging: Growing Old and Living Well in an Overtreated Society. Chapel Hill, NC: The University of North Carolina Press, 2011.
  • 20
    Mills JL. Data torturing. N. Engl. J. Med. 1993; 329: 11961199.
  • 21
    Smith GD, Ebrahim S. Data dredging, bias or confounding. Br. Med. J. 2002; 325: 14371438.
  • 22
    Wears RL, Cooper RJ, Magid D. Subgroups, reanalyses, and other dangerous things. Ann. Emerg. Med. 2005; 46: 253255.
  • 23
    Quinn TJ, Dawson J, Walters MR, Lees KR. Reliability of the modified Rankin scale: systematic review. Stroke 2009; 40: 33933395.